Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Cell Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD107a/LAMP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD107a/LAMP1 ECD-Fc Fusion Protein High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. HEK293 expressed for native glycosylation. |
View LAMP1 Products |
| Gene Delivery | CD107a/LAMP1 Promise-ORF / Lentivirus Full-length human ORF in lentiviral vectors for stable cell line generation. |
View LAMP1 Products |
| Benchmark Ab | Anti-CD107a/LAMP1 Recombinant Antibody Recombinant positive control matching standard clone sequences for assay validation. |
View LAMP1 Products |
| Validator | CD107a/LAMP1 siRNA Set Target-specific siRNA pool for knockdown verification in target-validation assays. |
View LAMP1 Products |
| Related Target A | CD107b/LAMP2 High-homology lysosomal membrane protein essential for specificity and cross-reactivity screening. |
View LAMP2 Products |
| Related Target B | CD56 Co-marker used alongside CD107a/LAMP1 in NK cell degranulation and cytotoxicity assays. |
View CD56 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Extensive N-glycosylation masking epitopes | HEK293 mammalian expression host ensures native post-translational modifications and authentic folding. |
| Subfamily off-target cross-reactivity | Homology counter-screening panels (LAMP1 vs. LAMP2) verified by mass spectrometry and high-purity SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Sequence-verified siRNA included for specificity checks |
Live CD107a/LAMP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD107a/LAMP1 therapeutics is intensifying, with major players shifting focus from traditional diagnostic mAbs to lysosomal-targeting chimeras (LYTACs) and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific surface translocation of CD107a/LAMP1 to bypass systemic lysosomal toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Biotech Innovators, Academic Medical Centers | Solid Tumors, Melanoma, Breast Cancer | Internalization Assay (Need high-purity, natively glycosylated ECD-Fc) |
| CAR-T/NK Potency Assays | Cell Therapy Developers, CROs | Hematological Malignancies, Solid Tumors | Degranulation validation (Need high-affinity benchmark antibodies) |
| LYTACs / Targeted Degraders | Degradation-focused Biopharma | Autoimmune Diseases, Advanced Cancers | Lysosomal binding kinetics (Need sequence-verified recombinant proteins) |